未知生产厂商
PF-08046031 (CD228V) is an early clinical-stage antibody-drug conjugate (ADC) targeting CD228 (melanotransferrin), originally developed by Pfizer and licensed to Medicus Pharma under a co-development and license agreement granting Medicus exclusive worldwide rights to the drug.
PF-08046031 (CD228V) is an early clinical-stage antibody-drug conjugate (ADC) targeting CD228 (melanotransferrin), originally developed by Pfizer and licensed to Medicus Pharma under a co-development and license agreement granting Medicus exclusive worldwide rights to the drug.
